# Study of BGB-11417 in Adult Participants With Mature B-cell Malignancies

> **NCT04883957** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **BeiGene** · enrollment: 64 (actual)

## Conditions studied

- Mature B-cell Malignancies

## Interventions

- **DRUG:** BGB-11417

## Key facts

- **NCT ID:** NCT04883957
- **Lead sponsor:** BeiGene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-07-05
- **Primary completion:** 2026-06
- **Final completion:** 2026-06
- **Target enrollment:** 64 (ACTUAL)
- **Last updated:** 2026-04-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04883957

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04883957, "Study of BGB-11417 in Adult Participants With Mature B-cell Malignancies". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT04883957. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*